About this trial
Acute gastrointestinal bleeding is potentially lethal in liver cirrhosis. Accurate assessment of prognosis is critical in a timely fashion. A novel model, CAGIB score, has been developed based on our Chinese multicenter retrospective study. Now, a prospective, international multicenter, observational study will be performed to further compare the performance of CAGIB versus Child-Pugh and MELD scores for evaluating the in-hospital mortality of patients with liver cirrhosis and acute gastrointestinal bleeding.
Eligibility criteria
Qualifiers
Patients with liver cirrhosis;
Patients with acute gastrointestinal bleeding presenting with hematemesis, melena, and/or hematochezia;
Adults (age≥18 years old).
Disqualifiers
Components of Child-Pugh, MELD, and CAGIB scores are not available;
In-hospital outcomes are not evaluable.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Xingshun Qi
Lead sponsor
General Hospital of Shenyang Military Region
Sponsor institution